Hims & Hers Health, Inc. Class A (HIMS)

Hims & Hers Health, Inc. stock has fallen by 37.74% over the last six months and 13.20% in the last month, as of January 14, 2026, but has increased by 30.00% over the last year. A 12% drop occurred in after-hours trading in August 2025 due to second-quarter revenue missing expectations, and Novo Nordisk terminated its Wegovy distribution partnership in June 2025. Despite these challenges, Q3 2025 saw a 49% year-over-year revenue increase to $599 million and a 21% year-over-year increase in subscribers. As of January 12, 2026, the stock saw a modest increase of 0.41% with significant options trading activity, and its implied volatility was among the lowest 10% observed over the past year, suggesting a stable market outlook.

Hims & Hers Health, Inc. exhibits some demand seasonality, with historical data suggesting a period of stronger performance between a Buy Date of October 27 and a Sell Date of March 22, resulting in a geometric average return of 36.96% above the S&P 500 Total Return Index. There is a "Very strong seasonality for November" noted for HIMS. The company's marketing investments are also expected to be higher as a result of seasonality.

Hims & Hers Health, Inc. is an American telehealth company founded in 2017 that operates a digital health and wellness platform connecting patients with licensed healthcare providers across various specialties, including Clinics/Outpatient Services, Telehealth, Online Pharmacy, and Healthcare Technology Systems. The company offers prescription medications, over-the-counter medications, and personal care products for chronic conditions like erectile dysfunction, hair loss, skin care, mental health, and weight loss, and has expanded to include treatments for low testosterone, perimenopause, menopause, and lab testing services. Hims & Hers operates on a direct-to-consumer, subscription-driven model, where customers pay for consultations and medications, without typically accepting insurance.

Hims & Hers Health, Inc. operates in all 50 states in the United States and has expanded into certain European markets, including the United Kingdom. In December 2025, the company entered the Canadian market through the acquisition of Livewell. The company also made acquisitions in Europe (Zava) and Canada (Livewell) to widen its total addressable market.

Hims & Hers Health, Inc. has focused on normalizing health and wellness challenges and innovating solutions to make healthcare more accessible, leveraging AI to enhance the patient experience and treatment solutions, including the launch of MedMatch. The company faced scrutiny regarding its compounded GLP-1 injections, which are not FDA-reviewed, leading to Novo Nordisk pulling out of a partnership in June 2025. Hims & Hers has continued to expand its platform, including the introduction of the Hers platform in the U.K. and its entry into Canada, which can positively impact its brand perception.

Hims & Hers Health, Inc. has a diverse ownership structure, with significant holdings by institutional investors such as BlackRock, Inc., Vanguard Group Inc, and Capital World Investors, and individual investors like Institutional Venture Management XV LLC, Jules A. Maltz, and Andrew Dudum (CEO). Institutional Venture Management XV LLC is the largest individual shareholder. As of January 12, 2026, institutional ownership was high at 96.34%.